Explore
Upload

DocSlides is a free service to upload presentations and documents.

Upload Now

Search Results for 'Tdf Hiv'

Tdf Hiv published presentations and documents on DocSlides.

Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV: ADVANCE and NAMSAL trials

Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV: ADVANCE and NAMSAL trials

  • luanne-stotts
  • 31 Slides

Progressive rises in weight and clinical obesity ...

EFFECTS ON RENAL FUNCTION OF A SWITCH FROM TENOFOVIR (TDF)

EFFECTS ON RENAL FUNCTION OF A SWITCH FROM TENOFOVIR (TDF)

  • tawny-fly
  • 20 Slides

M Harris, . S Guillemi. , K Chan, B Yip. ,. . M ...

Switching to TDF-FTC from ABC-3TC for Hyperlipidemia

Switching to TDF-FTC from ABC-3TC for Hyperlipidemia

  • trinity
  • 6 Slides

ROCKET II. Switching to TDF-FTC from ABC-3TC . for...

Switch to DOR-TDF-3TC vs. Continued Baseline Regimen

Switch to DOR-TDF-3TC vs. Continued Baseline Regimen

  • dorothy
  • 8 Slides

DRIVE SHIFT. Switch to Doravirine-TDF-3TC versus C...

Atazanavir + [Cobicistat or Ritonavir] + TDF-FTC (Phase 2)

Atazanavir + [Cobicistat or Ritonavir] + TDF-FTC (Phase 2)

  • zane419
  • 6 Slides

Study 105. Atazanavir + [Cobicistat or Ritonavir] ...

Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV

Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV

  • kylo
  • 31 Slides

Andrew Hill, Francois Venter, Eric . Delaporte. , ...

Switch from Efavirenz + ZDV-3TC to Efavirenz + TDF-FTC

Switch from Efavirenz + ZDV-3TC to Efavirenz + TDF-FTC

  • ramon803
  • 10 Slides

SWEET Trial . Switch to Efavirenz + TDF-FTC . SWEE...

Raltegravir + Darunavir/r versus TDF-FTC + Darunavir/r RADAR Trial

Raltegravir + Darunavir/r versus TDF-FTC + Darunavir/r RADAR Trial

  • keanu817
  • 7 Slides

RADAR Trial. Raltegravir. + Darunavir/r versus TD...

Schéma

Schéma

  • tatiana-dople
  • 22 Slides

de . l’étude. Critère. principal . –. pu...

1 Adam O’Neill Leonid

1 Adam O’Neill Leonid

  • celsa-spraggs
  • 137 Slides

Reyzin. Boston University. . A Unified Approach ...

HBV resistance and

HBV resistance and

  • calandra-battersby
  • 21 Slides

immune escape . mutants. Anders Boyd, MPH, . PhD....

Switch to DRV/r + RAL

Switch to DRV/r + RAL

  • debby-jeon
  • 5 Slides

SPARE . Study. SPARE Study: switch to DRV/r + RAL...

ID Week Review 2015

ID Week Review 2015

  • briana-ranney
  • 17 Slides

Brian R. Wood, MD. Assistant Professor of Medicin...

P1084s: Impact of maternal

P1084s: Impact of maternal

  • olivia-moreira
  • 0 Slides

tenofovir. . disoproxil. . fumarate. (TDF) . u...

Tyre Stewardship in Canada

Tyre Stewardship in Canada

  • sherrill-nordquist
  • 0 Slides

Presented to . New Zealand . Tyre. Industry Summ...

Florida AIDS Drug Assistance

Florida AIDS Drug Assistance

  • liane-varnes
  • 0 Slides

Program. Improving Health. . . Promoting Wellness...

Comparative effectiveness of first-line antiretroviral therapy regimens: results from a large real-

Comparative effectiveness of first-line antiretroviral therapy regimens: results from a large real-

  • min-jolicoeur
  • 0 Slides

implementation of Dolutegravir. Meireles MV. , Pa...

Common Pharmacomistakes in Advanced Illness

Common Pharmacomistakes in Advanced Illness

  • tawny-fly
  • 42 Slides

Common Pharmacomistakes in Advanced Illness Opioi...

Joel E. Gallant, MD, MPH

Joel E. Gallant, MD, MPH

  • mastervisa
  • 11 Slides

Medical Director, Specialty . Services. Southwest ...

Evolving Options for HBV Therapy:

Evolving Options for HBV Therapy:

  • desiron
  • 39 Slides

Navigating the New Treatment Landscape. Outline. I...

WHO ARV Forecasting Meeting

WHO ARV Forecasting Meeting

  • sistertive
  • 31 Slides

Geneva, March 19 - 20 , 2015 1 | Treatment and C...

Selecting an Initial Antiretroviral Therapy (ART) Regimen

Selecting an Initial Antiretroviral Therapy (ART) Regimen

  • cappi
  • 30 Slides

www.hivguidelines.org. Purpose of . This Guideline...

Target Date Funds and P

Target Date Funds and P

  • unita
  • 12 Slides

lan . S. ponsor Responsibilities. Marcia S. Wagner...

Renal and Bone Safety of

Renal and Bone Safety of

  • ashley
  • 16 Slides

Tenofovir. . Alafenamide. . vs. . Tenofovir. ....

Total Soluble and Insoluble Dietary Fibre Contents of Wild Growing E

Total Soluble and Insoluble Dietary Fibre Contents of Wild Growing E

  • alyssa
  • 7 Slides

302 Vol. 32, 2014, No. 3: 302–307Czech J. Fo...

Retirement Plan Consulting

Retirement Plan Consulting

  • oconnor
  • 30 Slides

Overview of Services. Table of Contents. About RPA...

EFV versus ATV + RTV, both with ABC-3TC or TDF-FTC

EFV versus ATV + RTV, both with ABC-3TC or TDF-FTC

  • felicity
  • 8 Slides

ACTG 5202. EFV versus ATV/r, both with ABC-3TC or ...

Switch from EFV plus ABC-3TC to EFV-TDF-FTC ROCKET-1 Trial

Switch from EFV plus ABC-3TC to EFV-TDF-FTC ROCKET-1 Trial

  • ricardo
  • 9 Slides

ROCKET-1 Trial. Switch from EFV + ABC-3TC to EFV-T...

Subjects with Renal Impairment Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Have Improved Renal and Bone Safety through 48 Weeks Study GS-US-292-0112

Subjects with Renal Impairment Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Have Improved Renal and Bone Safety through 48 Weeks Study GS-US-292-0112

  • micah
  • 16 Slides

Tenofovir. . Disoproxil. . Fumarate. to . Tenof...

Raltegravir plus Ritonavir-Boosted Darunavir NEAT001/ANRS 143 Trial

Raltegravir plus Ritonavir-Boosted Darunavir NEAT001/ANRS 143 Trial

  • matthew167
  • 11 Slides

NEAT001/ANRS 143 Trial. Darunavir/r + Raltegravir ...

COMING SOON:

COMING SOON:

  • luanne-stotts
  • 31 Slides

GENERIC ARVs. Tim Horn. Treatment Action Group. t...

TDF Microsoft Lync - Novembre 2010

TDF Microsoft Lync - Novembre 2010

  • faustina-dinatale
  • 9 Slides

Solutions & Architectures UC . Polycom. - Mi...

Switch to ATV/

Switch to ATV/

  • cheryl-pisano
  • 16 Slides

r. + RAL. HARNESS Study. ATV/. r. 300/100 mg ....

COMPARATIVE INVESTIGATIONS ON NUTRITIONAL COMPOSITIONS OF O

COMPARATIVE INVESTIGATIONS ON NUTRITIONAL COMPOSITIONS OF O

  • lois-ondreau
  • 55 Slides

GROWN CEREALS AND THEIR RELATIONSHIPS. Dr. . Mirj...

Les satisfactions : traitements efficaces, robustes, avec u

Les satisfactions : traitements efficaces, robustes, avec u

  • phoebe-click
  • 23 Slides

Dr Denis Lacoste. Bordeaux. Les satisfactions : ....

ART Resistance and Second Line Regimens

ART Resistance and Second Line Regimens

  • calandra-battersby
  • 0 Slides

Learning Objectives. Understand when to switch to...

Adaptive non-inferiority

Adaptive non-inferiority

  • cheryl-pisano
  • 0 Slides

margins under observable non-constancy. Brett Han...

Issues Affecting ART Success: Adherence, ARV Toxicity, Drug Interactions

Issues Affecting ART Success: Adherence, ARV Toxicity, Drug Interactions

  • pamella-moone
  • 0 Slides

Guidelines for the Use of Antiretroviral Agents i...

Duke Energy Carolinas ATC Calculation Process

Duke Energy Carolinas ATC Calculation Process

  • stefany-barnette
  • 0 Slides

ATC Training. December 15. th. , 2011. Agenda. Ob...

Tenofovir nephrotoxicity in resource limited setting of Western India : Higher rate of renal functi

Tenofovir nephrotoxicity in resource limited setting of Western India : Higher rate of renal functi

  • conchita-marotz
  • 0 Slides

A.Dravid. 1. ,A.Sadre. 2. ,S.Dhande. 1. , A.Borka...

Copyright © 2024 DocSlides. All Rights Reserved